Adamas is a pharmaceutical company that discovers and develops chrono-synchronous therapies to improve the daily lives of people affected by chronic neurologic disorders. Symptoms associated with neurologic disorders are often treated sub-optimally due to tolerability issues, which may limit the amount of drug that is present when patients need relief.
We pioneered a platform to develop medicines for chronic neurologic disorders called chrono-synchronous therapies. These therapies synchronize the temporal pattern of disease activity with the dynamics of drug profiles we invent without disrupting the brain’s master clock, e.g. circadian rhythm. We believe the lives of patients with neurologic disorders are improved when these factors operate in unison.
Our lead program, ADS-5102, is a chrono-synchronous amantadine therapy with an FDA-accepted New Drug Application (NDA) for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. LID is a form of dyskinesia associated with levodopa used to treat Parkinson’s disease. Over time, 90% of Parkinson’s disease patients on levodopa therapy will develop alternating periods of OFF (e.g. rigidity) and LID, as their disease progresses. LID is characterized by involuntary movements that are purposeless and unpredictable. The NDA for ADS-5102 in LID has a Prescription Drug User Fee Act (PDUFA) date of August 24, 2017 and, if approved, we plan to launch ADS-5102 in 2017.
We are also investigating ADS-4101, a chrono-synchronous lacosamide therapy, for the treatment of partial onset seizures in patients with epilepsy. The active ingredient in ADS-4101 is lacosamide, an anti-epileptic, previously approved by the FDA and currently marketed by UCB as VIMPAT® (lacosamide).
Additionally, our licensed assets for the treatment of moderate to severe Alzheimer’s disease, Namenda XR® (memantine hydrochloride) extended-release capsules and Namzaric® (memantine hydrochloride extended-release and donepezil hydrochloride) capsules, are currently marketed by Allergan. We are eligible to receive royalties on sales of Namenda XR and Namzaric beginning in June of 2018 and May of 2020, respectively.
Namenda XR® and Namzaric® are registered trademarks of Merz Pharma GmbH & Co. KGaA. VIMPAT® is a registered trademark of UCB.